Although ICIs have made great breakthroughs in cancer treatment, the low proportion of beneficiaries based on PD-1/PD-L1/CTLA-4, the high proportion of irAEs, and the high cost of treatment are the main problems to be solved urgently in current immunotherapy limited [75]. The gene discussed is PDCD1; the disease is cancer.